BioVie Inc. (BIVI) News

BioVie Inc. (BIVI): $0.45

0.01 (-1.26%)

POWR Rating

Component Grades








Add BIVI to Watchlist
Sign Up

Industry: Biotech




#215 of 359

in industry

Filter BIVI News Items

BIVI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BIVI News Highlights

  • BIVI's 30 day story count now stands at 2.
  • Over the past 11 days, the trend for BIVI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • FL and RAIL are the most mentioned tickers in articles about BIVI.

Latest BIVI News From Around the Web

Below are the latest news stories about BIOVIE INC that investors may wish to consider to help them evaluate BIVI as an investment opportunity.

Rail Vision and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / December 22, 2023 / RedChip Companies will air interviews with Rail Vision (NASDAQ:RVSN) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December ...

Yahoo | December 22, 2023

BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | December 11, 2023

The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie

Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.

Yahoo | December 1, 2023

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More

Regulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week.

Yahoo | November 30, 2023

BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data

BioVie (BIVI) stock plunges 61% in spite of positive phase III Alzheimer's Disease study results due to significant study conduct violations and protocol deviations reported by the company.

Yahoo | November 30, 2023

Why Is BioVie (BIVI) Stock Down 63% Today?

BioVie stock is falling after its Phase 3 clinical trial of its Alzheimer’s treatment candidate failed to show statistical significance.

William White on InvestorPlace | November 29, 2023

Why Is Farfetch (FTCH) Stock Down 50% Today?

Farfetch stock is falling on Wednesday as shares of FTCH have been volatile alongside going private reports, delayed earnings and more.

William White on InvestorPlace | November 29, 2023

Why Is Vivos Therapeutics (VVOS) Stock Up 290% Today?

Vivos Therapeutics stock is rocketing higher on Wednesday with heavy trading of VVOS shares following approval from the FDA!

William White on InvestorPlace | November 29, 2023

BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease

Table 1 Change from Baseline Figure 2 Improvements in Clinical Dementia Rating-Sum of Boxes Figure 3 Decrease of Neuroinflammatory Processes Figure 4 Age Deceleration Positive Trending Data from 57 Per-Protocol Patients Suggest NE3107 is Biologically Active and May Have Impact on Cognitive, Functional, and Biomarker Endpoints Sponsor Identified Issues Relating to Significant GCP Violations and Protocol Deviations, Which Allowed for Data from Only a Subset of Enrolled Patients to be Included in t

Yahoo | November 29, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Thursday!

William White on InvestorPlace | November 16, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!